Can-Fite BioPharma Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange Exchange announced today the initial results of its Phase IIb study in 253 rheumatoid arthritis (RA) patients. The study was a double-blind, placebo controlled, 12 weeks study that tested the effect of three doses of CF101 in combination with methotrexate (MTX) in comparison to MTX alone (that is, MTX plus placebo capsules). Preliminary results are being presented herein. The Company continues to conduct a full analysis of safety, efficacy and other data from the study. The preliminary results from this study support Can-Fite’s plans to advance its clinical program and to initiate additional clinical studies with CF101.

Back to news